Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 1, 2000, Pages 30-31

  Parving, Hans Henrik ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

ACE inhibitors; Diabetes; Hypertension; Renal protection; Renin angiotansin aldosterone system

Indexed keywords

ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; EDITORIAL; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; HUMANS; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0034160707     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.006     Document Type: Review

References (20)

1. Parving H-H, Østerby R, Anderson PW, Hsueh WA. Diabetic nephropathy. In: Brenner BM, editor.The Kidney. 5th ed. Philadelphia: Saunders, 1996:1864-1892.
2. Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998; 41:745-759.
3. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72:375-380.
4. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77:1925-1930.
5. Deinum J, Tarnow L, van Gool JM, et al. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant 1999; 14:1904-1911.
6. De'Oliveira JM, Price DA, Fisher NDL, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997; 52:771-777.
7. Wagner J, Gehlen F, Ciechanowicz A, Ritz E. Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 1999; 10:545-551.
8. Tarnow L, Gluud C, Parving H-H. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998; 13:1125-1130.
9. Parving H-H, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin-converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin-converting enzyme: observational follow up study. Br Med J 1996; 313:591-594.
10. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349:1787-1792.
11. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attennuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 1998; 128:982-988.
12. Marre M, Leblanc H, Suarez L, Guyenne T-T, Ménard J, Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 1987; 294:1448-1452.
13. Mogensen CE, Keane WF, Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346:1080-1084.
14. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving H-H. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319:24-25.
15. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577-581.
16. Hommel E, Parving H-H, Mathiesen ER, Edsberg B, Nielsen MD, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 1986; 293:466-470.
17. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effect of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293:471-474.
18. Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304:339-343.
19. Lewis E, Hunsicker L, Bain R, Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
20. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving H-H. Renoprotective effects of angiotensin II receptor blokade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; In press.